Mannkind 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 revenue was $101.9 million, up 24% from $82.1 million in the third quarter of 2025.
- Third-quarter commercial product revenue was $45 million, roughly double the $22.3 million in the prior-year quarter; FUROSCIX generated $22.4 million and Afrezza generated $19.3 million.
- Third-quarter royalty revenue increased 12% to $37.5 million, driven by Tyvaso DPI, while collaboration and services revenue was $19.4 million, compared with $26.5 million in the prior-year quarter.
- For the first nine months of 2026, total revenue was $301.4 million, up 27% from $237.0 million in the same period of 2025; commercial product revenue was $120.9 million, up 90%.
- Nine-month FUROSCIX revenue was $60.1 million, Afrezza revenue was $51.6 million, royalty revenue was $102.6 million, and collaboration and services revenue was $77.9 million.
- Third-quarter GAAP net loss was $23.2 million, compared with net income of $8.0 million in the third quarter of 2025; nine-month GAAP net loss was $58.9 million, compared with net income of $21.8 million in the prior-year period.
- Third-quarter expenses included $11.6 million related to the scPharma acquisition CVR and $5.2 million in amortization of acquired intangible assets; those items totaled $33.3 million year to date.
- By late October, roughly 75% of FUROSCIX shipments had moved to ReadyFlow, and more than 1,600 prescribers had written their first prescription.
- Afrezza total prescriptions grew 17% sequentially in the third quarter, and average monthly new-to-brand prescriptions were up nearly 80% compared with the second quarter.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon and welcome to the MannKind Corporation Third Quarter 2026 Financial Results Earnings Call. As a reminder, this call is being recorded on November 5, 2026, and will be available for replay on the MannKind Corporation website shortly after this call for approximately 90 days. This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from these expectations. For further information on the company's risk factors, please see Form 10-Q for the period ended September 30, 2026, the earnings release, and the slides prepared for this presentation. Joining us today from MannKind are Chief Executive Officer Michael Castagna and Chief Financial Officer Chris Prentiss. I'd now like to turn the call over to Mr. Castagna.
Please go ahead, sir. Thank you, operator, and good afternoon, everyone, and thank you for joining us for our Third Quarter 2026 Earnings Call.
I'll start with our quarter highlights, then provide some business updates while Chris walks us through our financial results, and I'll provide some closing remarks. Last quarter, I told you we had delivered all three catalysts we laid out for 2026. This quarter is about what comes next, moving from delivering catalysts to executing against them. Before we get into the quarter, I want to take a step back and look at how far MannKind has come. Five years ago, we were a company with roughly $75 million in revenue and one commercial product. Since then, we've grown revenue at a compound annual rate of more than 40%, and this year, we expect to be close to six times that size.
What I'm most proud of is how we've grown. We didn't get there on a single product or a single deal. First, our collaboration with United Therapeutics took off, and Tyvaso DPI became a blockbuster built on our DPI technology, and its royalties and manufacturing revenue has funded our transformation. Then we used this foundation to expand our commercial business, and today, FUROSCIX and Afrezza are leading our growth. That growth is now reaching the bottom line. We expect record revenue in Q4 will drive us to profitability as we close out the year, and none of this reflects our pipeline or external business development opportunities that can drive faster inorganic growth. Today, MannKind isn't a single-product story anymore. We're a diversified growth company with four FDA-approved products, no near-term IP cliffs, or a concentrated risk on any one brand or therapeutic area.
Today, we have three value engines driving growth. Each one plays a different role. First, we hit the key milestones laid out this year, and our commercial launches are growing nicely. FUROSCIX ReadyFlow is off to an exceptional start, with rapid conversion from the On-body Infusor and new patient growth, and the Afrezza pediatric launch is seeing strong early adoption. Second, our license agreement with United Therapeutics provides MannKind with cash flow that funds the development and will start to drop to the bottom line in 2027 and beyond. We anticipate $15 million in milestones from ralinepag DPI in 2027. Third, our DPI platform provides upside. This is long-term value creation. nintedanib DPI is our lung-targeted approach to IPF treatment, and key clinical evidence investors should look for is the data readout we're anticipating in the first half of 2028.
And with our out-licensed programs, Tyvaso DPI and ralinepag DPI, give us three potential paths in the IPF. Now let me hit the exciting highlights for the quarter. FUROSCIX ReadyFlow was approved, and by late October, roughly 75% of FUROSCIX shipments had moved to ReadyFlow, exceeding our internal expectations by several quarters. The marketing sales team did an amazing job, and it tells you physicians and patients were eager for this product. The Afrezza pediatric launch has exceeded all of our internal forecasts, including institutions and healthcare provider adoption, as well as our total prescriptions. In addition, average monthly new-to-brand prescriptions were up nearly 80% in Q3 compared with Q2, returning the brand to growth. On the pipeline, we reported positive phase I-B results for nintedanib DPI. INFLO-1 demonstrated the safety and tolerability, especially around cough in patients with IPF.
Several countries have now approved our new phase II protocol, enabling us to get clinical readout faster. And finally, we closed the $50 million private placement led by Frazier Life Sciences, which funded the $45 million CVR payment triggered by the ReadyFlow approval. This is a strong endorsement of our strategy from a high-quality, long-term investor. Now let's step back and look at the first nine months of the year. Total year-to-date revenue was $301 million, up 27% versus last year. Commercial product revenue from Afrezza and FUROSCIX more than doubled from $52 million to $112 million, up 116%, and royalties grew 8% to $103 million. The majority of our growth is now coming from products we promote, which will provide long-term sustainable revenue where we can bolt on other BD and pipeline opportunities to drive even faster growth in the coming years.
Yesterday, United Therapeutics put up excellent numbers for Tyvaso DPI, which returned to growth in the third quarter with $379 million in sales. On the call yesterday, they described stronger underlying demand, more consistent commercial execution, and increased adoption of higher-dose cartridges. Importantly, UT also pointed to an improvement in referrals beginning in September, with further benefits from its expanded commercial organization expected in the fourth quarter and well into 2027. Our royalties were $37.5 million, up 16% versus Q2. As the sole manufacturer of Tyvaso DPI, we continue to benefit from both royalties and manufacturing revenue. This recurring cash flow funds our diversified growth strategy that investors will start to see in Q4, as we expect this quarter to be the best quarter in the history of MannKind. Now let me turn to business updates, starting with FUROSCIX.
FUROSCIX ReadyFlow fundamentally took an administration that used to be measured by number of days in a hospital to seconds at home. This radical shift matters to patients and prescribers and will fundamentally transform how health systems think about managing fluid overload in the coming years. And I'll share with you some new market research we just conducted in a minute. We began shipping ReadyFlow mid-September, and in six weeks, nearly 75% of the prescriptions have already converted to ReadyFlow. The majority of patients starting ReadyFlow are new to brand, and more than 1,600 prescribers have written their first prescription. These are all encouraging signs this early in the launch, and we expect to see faster growth for the balance of the quarter and estimate Q4 sales should match the entire first half of 2027. How big can FUROSCIX be? Our independent research we just conducted with L.E.K.
reinforces the opportunity across nearly every stage of the fluid overload journey. For patients, the value is treatment outside the hospital with easier access and affordable out-of-pocket costs. For providers, it is another option to manage fluid overload, supported by clearer patient selection and dosing guidance and evidence of value to health systems. For shareholders, the opportunity is broader adoption and long-term growth. The research points to roughly 1 million patients annually at each stage, with physicians indicating they would prescribe FUROSCIX to a significant share at each of these stages. To capture this opportunity, we are focused on three priorities: generating evidence and practical guidance for physicians and IDNs, building awareness and expanding our reach in nephrology as well as IDNs, and simplifying patient access through hub and distribution improvements.
When you look back a year ago, we purchased scPharma, where analysts had forecast peak sales of roughly $500 million. Today, with the ReadyFlow approval, along with our incredible team leading us forward and the rapid adoption by prescribers, we are more excited than ever about the opportunity to help transform the management of fluid overload and the growth ahead. Now let me turn to Afrezza. Afrezza generated $19.3 million in net revenue in the third quarter, up about 5% versus third quarter last year, and total prescriptions grew 17% sequentially. Pediatric patients now represent about one in four Afrezza prescriptions, and the pediatric launch is now returning the brand to growth. I also want to be candid about our adult business, which has underperformed this year. There are three reasons why this is.
First, turnover in our field team slowed activity with some of our key prescribers. Second, several new insulin pumps launched in type 2 diabetes, which created more competition for the same patients. This was compounded by our third, which we can now look back and see, Afrezza is promotionally responsive, as our share of voice in adults was declined about 65% as we diverted our resources across the pediatric launch and nephrology to support FUROSCIX. As we look ahead to 2027, the opportunity to build on that early pediatric demand while re-energizing and focusing on the adult business will allow us to return the brand to growth. The early adoption of the pediatric launch picture is strong. Four months in, Afrezza's share of the pediatric mealtime insulin prescriptions is more than double its share in adults.
We never reached that share in the adult market, and in peds, we got there in a matter of months. Also, average monthly new-to-brand prescriptions for Afrezza are up nearly 80% versus the second quarter. In fact, Q3 alone came close to matching new patient starts for the entire first half. That is the trend we are focused on building upon. Behind that foundation is in place is more than 2,000 pediatric patients who have been treated since launch, with roughly 600 pediatric prescribers, and all 60 of our priority pediatric institutions have now prescribed Afrezza. We continue to see institutions adopt Afrezza and create back-to-school protocols as patients are now starting to return after having early success and creating a flywheel that we hope will continue to drive further growth ahead. With that, I will now turn it over to Chris to discuss our financial results.
Thanks, Mike, and good afternoon, everyone. Third quarter total revenue was $101.9 million, up 24% from $82.1 million in the third quarter of 2025. The headline this quarter is our continued diversification of our revenues. Commercial product revenue was $45 million, with the addition of FUROSCIX roughly double the $22.3 million in the prior year quarter, making commercial products our largest source of revenue. At the product level, FUROSCIX generated $22.4 million in net revenue. ReadyFlow shipments began in mid-September, and September was a record month for both prescribers and prescriptions. As Mike noted, demand shifted to ReadyFlow faster than we expected, and that pace tempered reported revenue in the quarter as patients and prescribers moved to ReadyFlow before the product was available for dispense. Additionally, based on launch inventories available, channel inventory was limited to just days. We estimate the transition reduced third quarter revenue by roughly $3 million.
With ReadyFlow now moving through the channel, we believe FUROSCIX will generate more revenue in the fourth quarter than it did in the entire first half of 2026. This is important, as ReadyFlow has a meaningfully lower cost of goods than the On-body Infusor, so the faster we convert, the faster that margin improvement flows through to the bottom line. Afrezza generated $19.3 million in net revenue, up 5% year over year, with total prescriptions up roughly 17% from the second quarter, driven by the pediatric launch. Because of our pediatric access program, which runs through the end of 2026, prescription growth is running ahead of revenue for now. That said, more than half of pediatric prescriptions are already being reimbursed by insurance, and converting the rest to paid coverage is a priority as we head into 2027.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
